BCG in Bladder Cancer Immunotherapy
BCG is a live attenuated strain of <i>Mycobacterium bovis</i> that is primarily used as a vaccine against tuberculosis. In the past four decades, BCG has also been used for the treatment of non-muscle invasive bladder cancer (NMIBC). In patients with NMIBC, BCG reduces the risk of tumor...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/13/3073 |
| _version_ | 1797480760897175552 |
|---|---|
| author | Song Jiang Gil Redelman-Sidi |
| author_facet | Song Jiang Gil Redelman-Sidi |
| author_sort | Song Jiang |
| collection | DOAJ |
| description | BCG is a live attenuated strain of <i>Mycobacterium bovis</i> that is primarily used as a vaccine against tuberculosis. In the past four decades, BCG has also been used for the treatment of non-muscle invasive bladder cancer (NMIBC). In patients with NMIBC, BCG reduces the risk of tumor recurrence and decreases the likelihood of progression to more invasive disease. Despite the long-term clinical experience with BCG, its mechanism of action is still being elucidated. Data from animal models and from human studies suggests that BCG activates both the innate and adaptive arms of the immune system eventually leading to tumor destruction. Herein, we review the current data regarding the mechanism of BCG and summarize the evidence for its clinical efficacy and recommended indications and clinical practice. |
| first_indexed | 2024-03-09T22:04:43Z |
| format | Article |
| id | doaj.art-a586be96cd534024bc477df925acbb7d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T22:04:43Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a586be96cd534024bc477df925acbb7d2023-11-23T19:43:56ZengMDPI AGCancers2072-66942022-06-011413307310.3390/cancers14133073BCG in Bladder Cancer ImmunotherapySong Jiang0Gil Redelman-Sidi1Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USAInfectious Diseases Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USABCG is a live attenuated strain of <i>Mycobacterium bovis</i> that is primarily used as a vaccine against tuberculosis. In the past four decades, BCG has also been used for the treatment of non-muscle invasive bladder cancer (NMIBC). In patients with NMIBC, BCG reduces the risk of tumor recurrence and decreases the likelihood of progression to more invasive disease. Despite the long-term clinical experience with BCG, its mechanism of action is still being elucidated. Data from animal models and from human studies suggests that BCG activates both the innate and adaptive arms of the immune system eventually leading to tumor destruction. Herein, we review the current data regarding the mechanism of BCG and summarize the evidence for its clinical efficacy and recommended indications and clinical practice.https://www.mdpi.com/2072-6694/14/13/3073BCGbladderimmunotherapy |
| spellingShingle | Song Jiang Gil Redelman-Sidi BCG in Bladder Cancer Immunotherapy Cancers BCG bladder immunotherapy |
| title | BCG in Bladder Cancer Immunotherapy |
| title_full | BCG in Bladder Cancer Immunotherapy |
| title_fullStr | BCG in Bladder Cancer Immunotherapy |
| title_full_unstemmed | BCG in Bladder Cancer Immunotherapy |
| title_short | BCG in Bladder Cancer Immunotherapy |
| title_sort | bcg in bladder cancer immunotherapy |
| topic | BCG bladder immunotherapy |
| url | https://www.mdpi.com/2072-6694/14/13/3073 |
| work_keys_str_mv | AT songjiang bcginbladdercancerimmunotherapy AT gilredelmansidi bcginbladdercancerimmunotherapy |